Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Mar 2014

Jomen Wataru, Kuroda Hiroyuki, Matsuno Teppei, Sato Masanori, Yamada Michiko, Abe Tomoyuki, Sakurai Tamaki, Fujii Shigeyuki, Maeda Masahiro, Fujita Miri, Kato Junji, Nojiri Shuichi

Abstract excerpt

A 68-year-old man complained of dizziness and was referred to our hospital by his primary physician for evaluation of an elevated leukocyte count. In April 2002, soon after the chronic phase of chronic myeloid leukemia had been diagnosed, he was treated with imatinib. In March 2010, imatinib treatment was completed and the BCR/ABL fusion gene had become undetectable by real time quantitative PCR. Subsequently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematocrit

Share to Imatinib Mesylate

Share to Leukocyte Count

Share to Phlebotomy

Share to Polycythemia Vera

Share to Remission Induction

Source

Identifiers

PMID: 24681942

Genes

BCR
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].PMID 24681942Read ↗

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.Semantic proximity Read ↗

Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.Semantic proximity Read ↗

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.Semantic proximity Read ↗

[Treatment of myeloproliferative neoplasms other than chronic leukemia].Semantic proximity Read ↗

[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

[Chronic Myelogenous Leukemia].Semantic proximity Read ↗

[Polycythemia vera and JAK-2 mutation in childhood: a case report].Semantic proximity Read ↗

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.Semantic proximity Read ↗

Polycythemia from mast cell activation syndrome: lessons learned.Semantic proximity Read ↗

Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.Semantic proximity Read ↗

[Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.